How big is the opioid-induced constipation treatment market today, and what are its future growth expectations?
The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.78 billion in 2024 to $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.
The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.
Get Your Free Sample of The Global Opioid-Induced Constipation Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp
What are the top drivers to the rising demand in the opioid-induced constipation treatment market?
The rise in the administration of opioids for cancer and non-cancer pain is expected to propel the growth of the opioid-induced constipation treatment market going forward. Cancer pain refers to pain associated with cancer and its treatment, while non-cancer pain refers to pain from conditions unrelated to cancer. Administration of opioids for cancer and non-cancer pain is driven by the need to effectively manage moderate to severe pain, considering factors such as the intensity and duration of pain, patient response to other treatments, and the overall goal of improving quality of life while minimizing potential risks of addiction and side effects. Opioid-induced constipation (OIC) treatment helps patients with cancer and non-cancer pain by relieving constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, in May 2021, according to the Government of Canada, a Canada-based federal administration, up to 8.3 million Canadians may experience chronic pain by 2025, and it is expected to reach up to 9.0 million by 2030. Therefore, the rise in the administration of opioids for cancer and non-cancer pain is driving the growth of the opioid-induced constipation treatment market.
How is the opioid-induced constipation treatment market segmented?
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone
Order your report now for swift delivery
Who are the top competitors in the opioid-induced constipation treatment market?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC
What significant trends should we anticipate in the opioid-induced constipation treatment market over the forecast period?
Major companies operating in the opioid-induced constipation treatment market are adopting strategic partnerships approach to develop innovative medicines. Strategic partnerships help opioid-induced constipation treatment companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach, and accelerating commercialization, ultimately driving innovation and growth in the opioid-induced constipation treatment industry. For instance, in November 2022, Kyowa Kirin Co. Ltd, a Japan-based biotechnology company, partnered with Grünenthal GmbH, Germany-based pharmaceutical company to integrate the solutions for patients. With this partnership, they aim to enhance the growth and global availability of a portfolio of life-changing pain management medicines, including treatments for opioid-induced constipation, breakthrough cancer pain, and osteoporosis.
Which regional trends are influencing the opioid-induced constipation treatment market, and which area dominates the industry?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Opioid-Induced Constipation Treatment Market Report 2025 Offer?
The opioid-induced constipation treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Opioid-induced constipation (OIC) treatment refers to the various approaches and medications used to manage constipation caused by the use of opioid medications. These treatments aim to alleviate the symptoms of constipation without compromising the pain-relieving effects of opioids, thereby improving the patient’s overall quality of life and maintaining effective pain management with both pharmacological with non-pharmacological approaches.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
